Cargando…

Priming increases the anti-tumor effect and therapeutic window of (177)Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1

BACKGROUND: (177)Lu-[DOTA(0), Tyr(3)]-octreotate ((177)Lu-octreotate) is used for treatment of patients with somatostatin receptor (SSTR) expressing neuroendocrine tumors. However, complete tumor remission is rarely seen, and optimization of treatment protocols is needed. In vitro studies have shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalmo, Johanna, Spetz, Johan, Montelius, Mikael, Langen, Britta, Arvidsson, Yvonne, Johansson, Henrik, Parris, Toshima Z., Helou, Khalil, Wängberg, Bo, Nilsson, Ola, Ljungberg, Maria, Forssell-Aronsson, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241264/ https://www.ncbi.nlm.nih.gov/pubmed/28097640 http://dx.doi.org/10.1186/s13550-016-0247-y

Ejemplares similares

Transcriptional effects of (177)Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice
por: Spetz, Johan, et al.
Publicado: (2019)

Hedgehog inhibitor sonidegib potentiates (177)Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice
por: Spetz, Johan, et al.
Publicado: (2017)

Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor
por: Montelius, Mikael, et al.
Publicado: (2018)

Distinct microRNA Expression Profiles in Mouse Renal Cortical Tissue after (177)Lu-octreotate Administration
por: Schüler, Emil, et al.
Publicado: (2014)

Potential Biomarkers for Radiation-Induced Renal Toxicity following (177)Lu-Octreotate Administration in Mice
por: Schüler, Emil, et al.
Publicado: (2015)

Hyperfractionated Treatment with (177)Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model
por: Elvborn, Mikael, et al.
Publicado: (2022)

Co-administration with A1M does not influence apoptotic response of (177)Lu-octreotate in GOT1 neuroendocrine tumors
por: Rassol, Nishte, et al.
Publicado: (2023)

Neuroblastoma xenograft models demonstrate the therapeutic potential of (177)Lu-octreotate
por: Romiani, Arman, et al.
Publicado: (2021)

Estimation of absorbed dose to the kidneys in patients after treatment with (177)Lu-octreotate: comparison between methods based on planar scintigraphy
por: Larsson, Maria, et al.
Publicado: (2012)

(177)Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
por: Hofving, Tobias, et al.
Publicado: (2019)

Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with (177)Lu-octreotate
por: Dalmo, Johanna, et al.
Publicado: (2014)

Transcriptional Response in Mouse Thyroid Tissue after (211)At Administration: Effects of Absorbed Dose, Initial Dose-Rate and Time after Administration
por: Rudqvist, Nils, et al.
Publicado: (2015)

Transcriptional response in normal mouse tissues after i.v. (211)At administration - response related to absorbed dose, dose rate, and time
por: Langen, Britta, et al.
Publicado: (2015)

Gene expression signature in mouse thyroid tissue after (131)I and (211)At exposure
por: Rudqvist, Nils, et al.
Publicado: (2015)

Transcriptional response to (131)I exposure of rat thyroid gland
por: Rudqvist, Nils, et al.
Publicado: (2017)

Age-related long-term response in rat thyroid tissue and plasma after internal low dose exposure to (131)I
por: Larsson, Malin, et al.
Publicado: (2022)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose (131)I exposure
por: Larsson, Malin, et al.
Publicado: (2020)

Correction: Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure
por: Larsson, Malin, et al.
Publicado: (2021)

Circadian rhythm influences genome-wide transcriptional responses to (131)I in a tissue-specific manner in mice
por: Langen, Britta, et al.
Publicado: (2015)

Renal function affects absorbed dose to the kidneys and haematological toxicity during (177)Lu-DOTATATE treatment
por: Svensson, Johanna, et al.
Publicado: (2015)

Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after (177)Lu-DOTA-Tyr(3)-octreotate treatment: a histological study in xenografted mice
por: Erlandsson, Ann, et al.
Publicado: (2011)

Data‐driven identification of tumor subregions based on intravoxel incoherent motion reveals association with proliferative activity
por: Jalnefjord, Oscar, et al.
Publicado: (2019)

In Vivo Measurement and Characterization of a Novel Formulation of [(177)Lu]-DOTA-Octreotate
por: Bailey, Dale L, et al.
Publicado: (2016)

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized (177)Lu-octreotate PRRT
por: Del Prete, Michela, et al.
Publicado: (2018)

Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
por: Purohit, Nupur K., et al.
Publicado: (2018)

Deconvolution of expression microarray data reveals (131)I-induced responses otherwise undetected in thyroid tissue
por: Langen, Britta, et al.
Publicado: (2018)

Effects of therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate on endocrine function
por: Teunissen, Jaap J. M., et al.
Publicado: (2009)

Non-targeted transcriptomic effects upon thyroid irradiation: similarity between in-field and out-of-field responses varies with tissue type
por: Langen, Britta, et al.
Publicado: (2016)

Multiparametric MR for non‐invasive evaluation of tumour tissue histological characteristics after radionuclide therapy
por: Montelius, Mikael, et al.
Publicado: (2019)

Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of (177)Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells
por: Shah, Rashmi G., et al.
Publicado: (2021)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)

Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019)

Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung
por: Kim, Chul, et al.
Publicado: (2020)

Evaluation of two intraoperative gamma detectors for assessment of (177)Lu activity concentration in vivo
por: Sandblom, Viktor, et al.
Publicado: (2017)

Age and sex effects across the blood proteome after ionizing radiation exposure can bias biomarker screening and risk assessment
por: Langen, Britta, et al.
Publicado: (2022)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

The IRI-DICE hypothesis: ionizing radiation-induced DSBs may have a functional role for non-deterministic responses at low doses
por: Langen, Britta, et al.
Publicado: (2020)

Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Forrer, Flavio, et al.
Publicado: (2009)

Effects of internal low-dose irradiation from (131)I on gene expression in normal tissues in Balb/c mice
por: Schüler, Emil, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mcho2at044bmpmq18hig21obiv